Related posts

Battle of the Top Dividend ETFs : Canada
Investor Insights

This summary was created by AI, based on 2 opinions in the last 12 months.

The experts provided mixed reviews for Bayer AG (BAYRY-OTC). Trevor Rose’s Insights highlighted the positive news from a US court ruling in favor of its Monsanto business, leading to a 10% stock jump. However, concerns were raised about high debt and limited growth potential. Another expert mentioned selling due to the Mansanto litigation. Overall, the outlook appears to be cautious with some positive developments.

Consensus
Cautious
Valuation
Undervalued
DON'T BUY
Bayer AG
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

There was some positive news on the 16th, after a US court ruled in favor of its Monsanto business in a lawsuit alleging that BAYRY's Roundup weedkiller products increase the risk of cancer. These claims were dismissed and the stock jumped over 10% that day. Recent quarterly results were positive and it beat on earnings and affirmed full-year guidance. It continues to be very cheap at 5.5x forward earnings but growth is not expected to be high while debt is also very high. We continue to not be overly excited here. 
Unlock Premium - Try 5i Free

chemicals
PAST TOP PICK
Bayer AG
(A Top Pick Jul 31/23, Down 51%)

He sold it last February. When he bought it was down 50% on the Mansanto litigation. He dumped up, classic risk management.

chemicals
TOP PICK
Bayer AG

It is priced at 50 cents on the dollar compared to its peers. In 2018 it bought Monsanto and the Roundup litigation halved the company. However it is being dealt with. It has three new drugs on the pharma side, one with no near term competitors when it comes off patent. It will probably spin out the herbicide business and sits at a very attractive price.    Buy 18  Hold 8  Sell 1

chemicals
DON'T BUY
Bayer AG
Their last quarter wasn't great; there was some positive news in their pharma pipeline. They sold assets from BASF to reduce net debt, which is now at Euros 36.5 billion. The debt-to-cash flow is still high, so they have a low credit rating. Their chemical side isn't growing. EPS are down 18%, which pressured the stock. JNJ has a better phrama pipeline and credit rating.
chemicals
BUY ON WEAKNESS
Bayer AG

On these big Chemicals you are always best to wait for an opportunity to get in. There isn't an urgent rush. This company is a monstrously big company.

chemicals
DON'T BUY
Bayer AG
Into pharmaceuticals and chemicals. Things seem to be moving along very well. Getting a little overpriced at these levels.
chemicals
Showing 1 to 6 of 6 entries
  • «
  • 1
  • »

Bayer AG(BAYRY-OTC) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 2

Stockchase rating for Bayer AG is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Bayer AG(BAYRY-OTC) Frequently Asked Questions

What is Bayer AG stock symbol?

Bayer AG is a American stock, trading under the symbol BAYRY-OTC on the US OTC (BAYRY). It is usually referred to as OTC:BAYRY or BAYRY-OTC

Is Bayer AG a buy or a sell?

In the last year, 2 stock analysts published opinions about BAYRY-OTC. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Bayer AG.

Is Bayer AG a good investment or a top pick?

Bayer AG was recommended as a Top Pick by on . Read the latest stock experts ratings for Bayer AG.

Why is Bayer AG stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Bayer AG worth watching?

2 stock analysts on Stockchase covered Bayer AG In the last year. It is a trending stock that is worth watching.

What is Bayer AG stock price?

On 2024-11-14, Bayer AG (BAYRY-OTC) stock closed at a price of $5.41.